Connor, Clark & Lunn Investment Management (CC&L)
AERI

Connor, Clark & Lunn Investment Management (CC&L)’s Aerie Pharmaceuticals AERI Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-12,100
Closed -$215K – 887
2015
Q3 		$215K Sell
12,100
-3,900
-24% -$70.6K ﹤0.01% 635
2015
Q2 		$282K Buy
+16,000
New +$293K ﹤0.01% 505

Other funds holding AERI

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s AERI Position: Q4 2015 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Aerie Pharmaceuticals (AERI) in Q4 2015, closing a stake of 12,100 shares — an estimated $215K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AERI in Q2 2015 and held it in 2 quarters. The position peaked at $282K in Q2 2015. 116 funds tracked by Wall St. Rank hold AERI as of Q4 2015.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Aerie Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 12,100 Aerie Pharmaceuticals shares in Q4 2015, an estimated $215K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Aerie Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Aerie Pharmaceuticals position peaked at $282K in Q2 2015.
  • 116 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2015.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2015, filed 11 Feb 2016.